A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Feasibility, and Preliminary Efficacy of NouvNeu001 in Patients With Advanced Parkinson's Disease. (NouvNeu001-01)

NCT07102342 Phase 1/Phase 2 RECRUITING

This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

Details

Lead sponsor	iRegene Therapeutics Co., Ltd.
Phase	Phase 1/Phase 2
Status	RECRUITING
Enrolment	5
Start date	2026-01-12
Completion	2032-09

Conditions

• Parkinson Disease

Interventions

• Human Dopaminergic Progenitor Cells

Primary outcomes

• Safety and Tolerability — 24 weeks and 48 weeks post-transplant
  Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

Countries

United States